Indian Herceptin Biosimilars Case Simmers
Executive Summary
The hotly contested case concerning biosimilar versions of Roche's Herceptin (trastuzumab) witnessed a seesaw shift after a division bench of the Delhi High Court held that the status prevailing prior to a stinging April 25 order against Biocon Ltd. and Mylan NV will continue to operate.
You may also be interested in...
Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad
Russia's Biocad has lashed out against Roche after being at the receiving end of what it claims are the Swiss multinational's 'scare tactics' against biosimilar competition in Sri Lanka. Biocad says it intends to pursue damages in the Sri Lankan case while Roche, which is standing its ground, has moved the Supreme Court in the island nation.
Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad
Russia's Biocad has lashed out against Roche after being at the receiving end of what it claims are the Swiss multinational's 'scare tactics' against biosimilar competition in Sri Lanka. Biocad says it intends to pursue damages in the Sri Lankan case while Roche, which is standing its ground, has moved the Supreme Court in the island nation.
Roche Backs Off Mircera Suit In India
Roche has dropped its suit against Intas Pharmaceuticals Ltd. over the alleged infringement of its patents pertaining to Mircera (methoxy polyethylene glycol-epoetin beta), after the Indian firm apparently established that its product is "different". Both sides, though, seemed to keep the matter alive, suggesting that they would seek appropriate remedies in the event of fresh "cause of action".